Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostics company, utilizes microRNAs, a collection of recently discovered non-coding control genes, to develop a broad array of tests for cancers and women’s health indications. These non-coding genes have demonstrated to be highly sensitive and tissue specific biomarkers. The company’s early recognition of microRNAs’ vast potential has led to great discovery and has the establishment of a leading intellectual property (IP) portfolio. For further information, visit the Company’s web site at www.rosettagenomics.com.
- 17 years ago
QualityStocks
Rosetta Genomics, Ltd. (NASDAQ: ROSG)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Adjourns Special Meeting Due to Lack of Quorum
TransCode Therapeutics (NASDAQ: RNAZ) announced that its April 21 special meeting has been adjourned to…
-
Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer
The global rare disease treatment market was estimated at $195.2 billion in 2024 and is…
-
Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Is ‘One to Watch’
High-Grade Copper Opportunity: 100% ownership of the New Craigmont Project, one of British Columbia’s most promising…